We are committed to transforming people’s lives by delivering therapeutics that change the course of autoimmune disease. This area includes many of the most challenging and burdensome chronic diseases for global healthcare systems, and on an individual level they often have significant impacts on quality of life.
Through scientific and clinical excellence, deep engagement with patient communities and commercial expertise, we are building our leadership in specialty pharmaceuticals for autoimmune disease to deliver long-term value to patients and the healthcare system.
We are currently advancing voclosporin for the treatment of lupus nephritis. In keeping with our expertise in specialty pharmaceuticals, we are also actively pursuing a broader portfolio of innovative drugs for autoimmune disease.